You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.
The team will launch a Phase II study to validate early-stage gastric cancer micro-RNA biomarkers and eventually develop liquid biopsy tests.
Metabolon's Precision Metabolomics platform identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways.
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
Zeesan's test may be used by any CLIA-certified high-complexity lab, while UCSD's test, which uses pooled samples, must be performed by the university.
Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.
The company believes the pandemic will accelerate the adoption of its cancer diagnostics as patients and doctors look for faster and more convenient tests.
The test, which has Emergency Use Authorization from the US Food and Drug Administration, is designed to detect the SARS-CoV-2 ORF1ab, N, and E genes.
For the three months ended June 30, the genomic testing firm reported total revenues of $20.7 million.
The firm reported that revenues from screening products fell 34 percent year over year, but that it took in $34.6 million in revenues from COVID-19 testing.
The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.
Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.
On a conference call to discuss the company's third quarter financial results, executives said they increased molecular test production by 50 percent during the quarter.
Strong demand for the firm's COVID-19 molecular tests for the Panther and Panther Fusion platforms offset revenue declines in other areas of the business.
The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.
The group will use Akoya's Phenoptics platform to discover biomarkers for selecting neoadjuvant and adjuvant immunotherapies for early-stage breast cancer patients.
MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.
The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.
Both of the RT-PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in a variety of swab samples and other specimens.
The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.
Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.
Gene length is associated with lifespan in a comparative genomics study appearing in the Proceedings of the National Academy of Sciences that draws on the whale shark genome.
In Nucleic Acids Research this week: effort to annotate the rat transcriptome, web-based resource to characterize marine microbes, and more.